![Quiver Logo](/static/img/logo-icon.png)
![MREO logo](https://quiver-logos.s3.us-east-2.amazonaws.com/mreo.png)
Mereo BioPharma Group plc American Depositary Shares
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MREO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of MREO by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by MREO's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to MREO
Recent picks made for MREO stock on CNBC
ETFs with the largest estimated holdings in MREO
Flights by private jets registered to MREO
![Quiver Logo](/static/img/logo-icon.png)